On this page

What happened

FDA’s July 13, 2026 update described DEA’s July 1 notice of intent to start temporary scheduling of 7-hydroxymitragynine above a proposed threshold and three synthetic derivatives: mitragynine pseudoindoxyl, MGM-15 and MGM-16. HHS opened a separate public-comment process about the threshold. The source records the agencies’ actions at that point in July; it does not announce that the notice itself had already become a final scheduling order.

Why it matters

The agencies said the proposed action targeted concentrated and synthetic 7-OH products, rather than natural kratom leaf containing only naturally occurring trace amounts. HHS asked for evidence about the amount or concentration representing an imminent public-safety hazard and possible alternative ways to express that threshold. This distinction matters because leaf material, concentrated extracts and synthetic compounds are not interchangeable exposure categories merely because their marketing uses the same botanical name.

Scope and limitations

FDA explained that a temporary order could be issued no sooner than 30 days after the notice, subject to the statutory conditions. A comment period, a proposal and a final order are different steps; the July update should not be used as a complete account of the law at a later date. This is U.S. regulatory news about opioid-related substances, not evidence of cognitive benefit or a legal determination for Turkey. The original agency page is the reference for the historical update.

This sourced news summary and translation were prepared with AI assistance. Source links, the news date and research limitations are disclosed; this is not a claim of independent medical expert review. News production method.

Sources

Research news is not medical advice or a recommendation to use a substance. Read findings in the context of the study design, participants and limitations. Editorial standards.

← All news